Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

1. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. (PubMed)

Parenteral versus oral iron therapy for adults and children with chronic kidney disease. BACKGROUND: The anaemia seen in chronic kidney disease (CKD) may be exacerbated by iron deficiency. Iron can be provided through different routes, with advantages and drawbacks of each route. It remains unclear whether the potential harms and additional costs of intravenous (IV) compared with oral iron are justified. This is an update of a review first published in 2012. OBJECTIVES: To determine (...) the benefits and harms of IV iron supplementation compared with oral iron for anaemia in adults and children with CKD, including participants on dialysis, with kidney transplants and CKD not requiring dialysis. SEARCH METHODS: We searched the Cochrane Kidney and Transplant Register of Studies up to 7 December 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference

2019 Cochrane

2. Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronic kidney disease

Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronic kidney disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs

2019 Health Canada - Drug and Health Product Register

3. Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension

Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension Page 1 of 6 TER005 December 2018 Topic Exploration Report Topic explorations are designed to provide a high-level briefing on new topics submitted for consideration by Health Technology Wales. The main objectives of this report are to: 1. Inform discussions on new topics received by HTW. 2. Determine the quantity and type of evidence available (...) on a topic. 3. Assess the topic against HTW selection criteria. Topic: Albumin:creatinine ratio (ACR) ) testing compared to protein:creatinine ratio (PCR) testing for the detection of proteinuria in patients with hypertension and/or chronic kidney disease Topic exploration report number TER005 Referrer: Dr Soha Zouwail, Consultant Chemical Pathologist, Cardiff and Vale University Health Board Topic exploration undertaken by: Health Technology Wales Aim of Search Health Technology Wales researchers

2019 Health Technology Wales

4. Gout medication may slow progression of chronic kidney disease

Gout medication may slow progression of chronic kidney disease Signal - Gout medication may slow progression of chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover Gout medication may slow progression of chronic kidney disease Published on 20 February 2018 In people with existing kidney disease, one in four will have worse disease within six to 12 months. Uric acid-lowering drugs such as allopurinol halve the risk of disease progression over this period. They also (...) reduce heart attack or stroke by 60%. Uric acid, the cause of gout, is produced when proteins are broken down by the body. It is excreted by the kidneys and often builds up in people with chronic kidney disease. It is not certain whether increased uric acid causes progression of kidney disease or is simply a marker of its severity. This review included 16 small trials of 1,211 people with moderate chronic kidney disease from a variety of causes which were allocated to take a uric acid lowering

2019 NIHR Dissemination Centre

5. Uncertainty persists over choice of phosphate binders for chronic kidney disease

Uncertainty persists over choice of phosphate binders for chronic kidney disease Signal - Uncertainty persists over choice of phosphate binders for chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover Uncertainty persists over choice of phosphate binders for chronic kidney disease Published on 30 August 2016 NICE recommend calcium-based phosphate binding medicines for people with chronic kidney disease, however, new research suggests non-calcium based alternatives might (...) lead to a lower risk of death. The review is best viewed alongside other reviews which look at different aspects of chronic kidney disease. The totality of research and cost effectiveness will need to be considered if practice recommendations are to change. In this review, calcium-based phosphate binders were associated with increased risk of death compared with non-calcium alternatives, but there was no difference in the risk of cardiovascular death or hospitalisation. Effects of these agents

2019 NIHR Dissemination Centre

6. New generation anticoagulants may be safer than warfarin for people with chronic kidney disease

New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Signal - New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Published on 26 April 2016 Newer generation anticoagulants appear to reduce the risk of bleeding compared with older anticoagulants like warfarin (...) , when used to prevent clots in people who also have mild to moderate chronic kidney disease. This group of drugs, called direct oral anticoagulants, have been well researched in healthy people with atrial fibrillation or at risk of thromboembolism but this was the first review to look at their safety, in terms of bleeding and risk of bleeding within the brain, in people with kidney disease. As a group, these newer drugs appear safer than older anticoagulants such as warfarin. Evidence from

2019 NIHR Dissemination Centre

7. Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery

Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery 29932345 2018 11 15 1535-4970 198 10 2018 Nov 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery. 1279-1287 10.1164/rccm.201710-2150OC No medical intervention has been identified that decreases acute kidney injury and improves renal outcome at 1 year after (...) the gas exchanger during cardiopulmonary bypass and by inhalation for 24 hours postoperatively. The primary outcome was as follows: oxidation of ferrous plasma oxyhemoglobin to ferric methemoglobin was associated with reduced postoperative acute kidney injury from 64% (control group) to 50% (nitric oxide group) (relative risk [RR], 0.78; 95% confidence interval [CI], 0.62-0.97; P = 0.014). Secondary outcomes were as follows: at 90 days, transition to stage 3 chronic kidney disease was reduced from 33

2018 EvidenceUpdates

8. Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease. (PubMed)

Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease. BACKGROUND: Maintaining long-term vascular access patency is necessary for high quality haemodialysis (HD) treatment of patients with the terminal and most serious stage of chronic kidney disease (CKD) - end-stage kidney disease (ESKD). Oral supplementation with omega-3 fatty acids (ω-3FA) may help to prevent blockage of the vascular access by reducing the risk of thrombosis and stenosis (...) . OBJECTIVES: To evaluate the efficacy and safety of ω-3FA supplementation versus placebo or no treatment for maintaining vascular access patency in ESKD patients undergoing HD. SEARCH METHODS: We searched the Cochrane Kidney and Transplant Register of Studies up to 23 July 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical

2018 Cochrane

9. Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease

Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease 30235475 2018 10 01 2567-689X 118 10 2018 Oct Thrombosis and haemostasis Thromb. Haemost. Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease. 1839-1846 10.1055/s-0038-1669426 The clinical benefit of anti-platelet agents in patients (...) with chronic kidney disease (CKD) is uncertain. In addition, the risk-benefit ratio of potent oral P2Y12-adenosine diphosphate (ADP) receptor antagonists (PPAs), namely, prasugrel and ticagrelor, compared with clopidogrel in CKD patients suffering from acute coronary syndrome (ACS) remains unknown. We performed a meta-analysis of all studies comparing the clinical outcomes of PPA and clopidogrel therapy in CKD patients suffering from ACS. We searched PubMed, the Cochrane library, Google Scholar, Clinical

2018 EvidenceUpdates

10. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment

Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment 30304329 2018 11 05 2168-6114 178 11 2018 Nov 01 JAMA internal medicine JAMA Intern Med Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment. 1526-1533 10.1001/jamainternmed.2018.4463 Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines. To assess the association of allopurinol use in gout with the risk of developing chronic kidney disease (...) propensity score matched 4760 initiators of allopurinol (≥300 mg/d) to the same number of noninitiators of allopurinol, excluding those with chronic kidney disease stage 3 or higher or urate-lowering therapy use before their gout diagnosis. Allopurinol initiation at a dose of 300 mg or more per day. Development of chronic kidney disease stage 3 or higher. Of the 4760 allopurinol initiators (3975 men, 785 women) and same number of noninitiators (3971 men, 789 women), 579 and 623, respectively, developed

2018 EvidenceUpdates

11. Sonographic Venous Velocity Index Identifies Patients with Chronic Kidney Disease and Severe Diastolic Dysfunction (PubMed)

Sonographic Venous Velocity Index Identifies Patients with Chronic Kidney Disease and Severe Diastolic Dysfunction 30370402 2018 11 14 2509-596X 4 4 2018 Oct Ultrasound international open Ultrasound Int Open Sonographic Venous Velocity Index Identifies Patients with Chronic Kidney Disease and Severe Diastolic Dysfunction. E142-E148 10.1055/a-0684-9483 Diagnosing cardiorenal syndrome (CRS) in patients with chronic kidney disease (CKD) continues to remain challenging in outpatient practice (...) 101674542 2199-7152 cardiorenal syndrome chronic kidney disease renal ultrasound renal venous congestion 2018 02 03 2018 06 04 2018 07 22 2018 10 30 6 0 2018 10 30 6 0 2018 10 30 6 1 ppublish 30370402 10.1055/a-0684-9483 uio0152 PMC6202069 J Am Coll Cardiol. 2004 Jan 7;43(1):61-7 14715185 Eur J Intern Med. 2013 Mar;24(2):177-82 23266236 World J Nephrol. 2017 May 6;6(3):123-131 28540202 Circulation. 2010 Jun 15;121(23):2592-600 20547939 JACC Heart Fail. 2016 Aug;4(8):674-82 27179835 J Am Coll Cardiol

Full Text available with Trip Pro

2018 Ultrasound international open

12. Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study. (PubMed)

Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study. Background: Whether the increased incidence of chronic kidney disease (CKD) during intensive systolic blood pressure (SBP) lowering is accompanied by intrinsic kidney injury is unknown. Objective: To compare changes in kidney damage biomarkers between incident CKD case participants and matched control participants as well as between case participants in the intensive (<120 mm (...) Hg) versus the standard (<140 mm Hg) SBP management groups of SPRINT (Systolic Blood Pressure Intervention Trial). Design: Nested case-control study within SPRINT. Setting: Adults with hypertension without baseline kidney disease. Participants: Case participants (n = 162), who developed incident CKD during trial follow-up (128 in the intensive and 34 in the standard group), and control participants (n = 162) without incident CKD, who were matched on age, sex, race, baseline estimated

2018 Annals of Internal Medicine

13. Low protein diets for non-diabetic adults with chronic kidney disease. (PubMed)

Low protein diets for non-diabetic adults with chronic kidney disease. BACKGROUND: Chronic kidney disease (CKD) is defined as reduced function of the kidneys present for 3 months or longer with adverse implications for health and survival. For several decades low protein diets have been proposed for participants with CKD with the aim of slowing the progression to end-stage kidney disease (ESKD) and delaying the onset of renal replacement therapy. However the relative benefits and harms (...) with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. SELECTION CRITERIA: We included randomised controlled trials (RCTs) or quasi RCTs in which adults with non-diabetic chronic kidney disease (stages 3 to 5) not on dialysis were randomised to receive a very low protein intake (0.3 to 0.4 g/kg

2018 Cochrane

15. Do thiazides work in patients with chronic kidney disease?

Do thiazides work in patients with chronic kidney disease? Do Thiazides Work in Patients With Chronic Kidney Disease? – Clinical Correlations Search Do Thiazides Work in Patients With Chronic Kidney Disease? October 4, 2018 By Hannah Friedman Peer Reviewed It is a commonly seen scenario on the wards: a patient with a past medical history of heart failure and stage 4 chronic kidney disease presents with progressive shortness of breath and worsening lower extremity edema. The patient is diagnosed (...) ). However, recent literature . [1] Recent reports estimate that 13.1% of the US population has chronic kidney disease (CKD), with 8% having at least stage 3 CKD. [2] These patients have a , [3] and this risk worsens as the disease progresses. Thiazides and thiazide-like diuretics act on the distal convoluted tubule of the nephron, specifically on the . [4] This mechanism makes thiazides useful not just as antihypertensives, but also as diuretics in volume-overloaded patients. Thiazides first came

Full Text available with Trip Pro

2018 Clinical Correlations

16. PPI Use and Increased Risk of Chronic Kidney Disease

PPI Use and Increased Risk of Chronic Kidney Disease "PPI Use and Increased Risk of Chronic Kidney Disease" by Trevor Romo < > > > > > Title Author Date of Graduation Summer 8-11-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Proton pump inhibitors (PPIs) are a class of gastric-acid reducing medications indicated for conditions including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), Zollinger (...) -Ellison syndrome, and erosive esophagitis. With 119 million PPI prescriptions filled in 2009, these are currently one of the most commonly prescribed classes of medication. The current list of known side effects for PPIs includes pneumonia, Clostridium difficile , hip fractures, acute interstitial nephritis (AIN), and malabsorption. The purpose of this review is to investigate if PPI use is also associated with an increased risk in developing chronic kidney disease (CKD) Methods: An exhaustive

2018 Pacific University EBM Capstone Project

17. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial 30002098 2018 07 13 1524-4539 2018 Jul 12 Circulation Circulation Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial. CIRCULATIONAHA.118.034818 10.1161/CIRCULATIONAHA.118.034818 Background -Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced (...) ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate-to-severe chronic kidney disease are unknown. Methods -UK HARP-III was a randomised double-blind trial which included 414 participants with an estimated glomerular filtration rate (GFR) 20-60 mL/min/1.73m 2 who were randomly assigned to sacubitril/valsartan 97/103 mg twice daily versus irbesartan 300 mg once daily. The primary outcome was measured GFR (mGFR) at 12 months using analysis of covariance

Full Text available with Trip Pro

2018 EvidenceUpdates

18. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. (PubMed)

Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. BACKGROUND: Diabetes is the commonest cause of chronic kidney disease (CKD). Both conditions commonly co-exist. Glucometabolic changes and concurrent dialysis in diabetes and CKD make glucose-lowering challenging, increasing the risk of hypoglycaemia. Glucose-lowering agents have been mainly studied in people with near-normal kidney function. It is important to characterise existing knowledge (...) certainty evidence). SGLT2 inhibitors may reduce weight (5 studies, 1029 participants: MD -1.41 kg, -1.8 to -1.02; I 2 = 28%) and albuminuria (MD -8.14 mg/mmol creatinine, -14.51 to -1.77; I 2 = 11%; low certainty evidence). SGLT2 inhibitors may have little or no effect on the risk of cardiovascular death, hypoglycaemia, acute kidney injury (AKI), and urinary tract infection (low certainty evidence). It is uncertain whether SGLT2 inhibitors have any effect on death, end-stage kidney disease (ESKD

2018 Cochrane

19. Chronic kidney disease

Chronic kidney disease Chronic kidney disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic kidney disease Last reviewed: August 2018 Last updated: September 2018 Summary Proteinuria or haematuria, and/or a reduction in the glomerular filtration rate, for more than 3 months' duration. The most common causes are diabetes mellitus and hypertension. The majority of people are asymptomatic, and the diagnosis (...) is determined only by laboratory studies. Glycaemic control for diabetic nephropathy and optimisation of blood pressure are key in slowing the progression of disease. Increased risk for cardiovascular disease. Definition Chronic kidney disease (CKD), also known as chronic renal failure, is defined by either a pathological abnormality of the kidney, such as haematuria and/or proteinuria, or a reduction in the glomerular filtration rate to <60 mL/minute/1.73 m² for ≥3 months' duration. Kidney Disease

2018 BMJ Best Practice

20. Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial

Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial 30092952 2018 08 10 1558-3597 72 7 2018 Aug 14 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial. 754-765 S0735-1097(18)35196-9 10.1016/j.jacc.2018.05.057 The optimal revascularization strategy for patients with left main coronary artery disease (LMCAD) and chronic kidney disease (CKD (...) Pieter AP Erasmus University Medical Center, Rotterdam, the Netherlands. Stone Gregg W GW Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York. Electronic address: gs2184@columbia.edu. eng ClinicalTrials.gov NCT01205776 Journal Article United States J Am Coll Cardiol 8301365 0735-1097 chronic kidney disease coronary artery bypass grafting coronary artery disease left main percutaneous

2018 EvidenceUpdates